Recombinant factor IX

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 261-265

  White II, Gilbert C ^a   Beebe, Aime ^a   Nielsen, Brenda ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9;

BIOCHEMISTRY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG PURIFICATION; DRUG SAFETY; DRUG SYNTHESIS; HEMOPHILIA; HEMOPHILIA B; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROTEIN PROCESSING; RECOMBINANT DNA TECHNOLOGY; RISK; VIRUS INFECTION;

EID: 0030857349     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657536     Document Type: Conference Paper

References (19)

1. 2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem 1989; 264: 20320-20325.
2. Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B. Recognition site directing vitamin K-dependent γ-carboxylation residues in the propeptide of factor IX. Cell 1987; 48: 185-191.
3. Wasley LC, Rehemtulla A, Bristol JA, Kaufman RJ. Pace/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem 1993; 268: 8458-8465.
4. Fernlund P, Stenflo J. β-Hydroxyaspartic acid in vitamin K-depedent proteins. J Biol Chem 1983; 258: 12509-12512.
5. Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819.
6. Gerritzen A, Schneweis KE, Brackman H-H, Oldenburg J, Hanfland P, Gerlich, WH, Caspari G. Acute hepatitis A in haemophiliacs. Lancet 1992; 340: 1231-1232.
7. Mariani G, di Paolantonio T, Baklaya R, Morfini M, Mannucci PM. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent treated factor VIII concentrate: Parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. Transfusion 1993; 33: 814-818.
8. Flores G, Juarez JC, Montoro JB, et al. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia 1995; 1: 115-117.
9. Hepatitis A among persons with hemophilia who received clotting factor concentrate - United States, September-December 1995, MMWR (Atlanta, Ga: Centers for Disease Control. US Department of Health and Human Services publication) 1996; 45: 29-32.
10. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Brit J Haemat 1996; 93: 457-459.
11. Ragni MV, Koch WC, Jordan JA. Parvovirus B19 infection in patients with hemophilia. Transfusion 1996; 36: 238-241.
12. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant γ-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-9628.
13. Bond MD, Patel H, Huberty MC, et al. Structural and biological characterization of Gla-related isoforms of recombinant human factor IX shows that Gla36 and Gla40 are not essential for in vitro clotting activity. Thrombos Haemostas 1995; 73: 1167-1168.
14. Gillis S, Furie BC, Furie B, Patel H, Huberty MC, Switzer M, Foster WB, Scoble HA, Bond MD. γ-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci 1997; 6: 185-196.
15. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Lappanen SD, Rup BJ, Keith Jr JC, Garzone PD, Schaub RG. Recombinant factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996; 88: 2803-2810.
16. Kim HC, McMillan CW, White II GC, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-575.
17. Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL. Coagulation factor IX: Successful surgical experience with a purified factor IX concentrate. Am J Hemat 1992; 40: 210-215.
18. Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thrombos Haemostas 1993; 70: 768-773.
19. Poon M-C, Aledort LM, Anderle K, Kunschak M, Morfini M. Comparison of the recovery and half-life of a high purity factor IX concentrate with those of a factor IX complex concentrate. Transfusion 1995; 35: 319-323.